Fig. 1
From: Distribution of chimeric antigen receptor-modified T cells against CD19 in B-cell malignancies
Basic information of CD19 CAR-T cells. a. The construction of CAR. FMC63-derived scFv with a 4-1BB co-stimulatory domain and a CD3ζ signaling domain. b. The manufacturing process of CAR-T products. CD3+ T cells were purified from PBMC and stimulated with CD3/CD28 Dynabeads. The T cells were then transfected with CAR lentivirus within 48 h and cultured for 9 days